Table 1: HDACi combination regimens currently in clinical trials. Partial list of clinical trials evaluating the combination of HDACi with other anticancer agents discussed in this paper (source: http://www.clinicaltrials.gov/, http://www.cancer.gov/clincialtrials).

HDACi Other Intervention Tumor Type Entinostat (SNDX-275) azacitidine leukemia, MDS, colorectal cancer, NSCLC Mocetinostat (MGCD0103) azacitidine MDS Panobinostat (LBH589) azacitidine MDS, CML, AML bortezomib peripheral T cell lymphoma, NK/T cell lymphoma, MM, pancreatic cancer bortezomib, dexamethasone MM decitabine MDS, AML decitabine, temozolomide melanoma radiation therapy prostate cancer, esophageal cancer, head and neck cancer PCI-24781 doxorubicin sarcoma Romidepsin bortezomib myeloma Valproic acid azacitidine advanced cancers azacitidine, ATRA AML, MDS decitabine, ATRA AML radiation therapy, bevacizumab children with high grade gliomas radiation therapy, temozolomide high grade gliomas, brain tumors Vorinostat azacitidine AML, MDS, DLBCL, lymphoma, MM, NSCLC, Non-Hodgkin's lymphoma bortezomib, AMG 655 lymphoma bortezomib, dexamethasone MM cisplatin, pemetrexed, radiation therapy NSCLC cisplatin, radiation therapy squamous cell carcinoma gemtuzumab ozogamicin, azacitidine AML marizomib (NPI-0052) NSCLC, pancreatic cancer, melanoma, lymphoma paclitaxel, radiation therapy NSCLC radiation therapy brain metastases, NSCLC, pancreatic cancer, pelvic cancer radiation therapy, fluorouracil pancreatic adenocarcinoma

ATRA: all-trans retinoic acid, MM: multiple myeloma, NSCLC: nonsmall cell lung carcinoma, AML: acute myeloid leukemia, CML: chronic myelogenous leukemia, MDS: myelodysplastic syndrome, and DLBCL: Diffuse large B-cell lymphoma.